12/15/2022 8:16:13 AM
Kintara Therapeutics Gets Orphan Drug Designation For VAL-083 For Treatment Of Diffuse Intrinsic Pontine Glioma
11/30/2022 8:08:44 AM
Kintara Therapeutics Says Regains Compliance With Nasdaq Minimum Bid Price Requirement
11/28/2022 8:05:19 AM
Kintara Granted Fast Track Designation From FDA For REM-001 For Cutaneous Metastatic Breast Cancer; Stock Up
11/11/2022 8:05:18 AM
Kintara Therapeutics Announces One-for-Fifty Reverse Stock Split
10/19/2022 8:17:53 AM
Kintara Pauses REM-001 Program In Cutaneous Metastatic Breast Cancer To Conserve Funds
6/15/2022 9:05:44 AM
Kintara Therapeutics Granted Fast Track Designation From FDA For VAL-083 For Newly-Diagnosed Glioblastoma
6/3/2022 9:02:10 AM
Kintara Granted 180-Day Extension To Meet Nasdaq Minimum Bid Price Requirement
5/27/2022 10:10:13 AM
Kintara Reports First European Site Activation In GCAR Phase 2/3 Trial For Glioblastoma
2/11/2022 8:26:48 AM
Kintara Therapeutics Q2 Loss/shr $0.12 Vs. Loss/shr $0.22 Prior Year
2/11/2022 8:26:02 AM
Kintara Therapeutics Q2 Loss/shr $0.12 Vs. Loss/shr $0.22 Prior Year
11/18/2021 8:10:42 AM
Kintara Presents Updates On Two Phase 2 Clinical Studies On Neuro-oncology